Breaking News

Monday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Galecto announces publication of GB0139 Phase 2a IPF results » 08:14
11/30/20
11/30
08:14
11/30/20
08:14
GLTO

Galecto

$16.18 /

+0.18 (+1.13%)

Galecto announced the…

Galecto announced the publication of a paper detailing full results from a phase 2a study of GB0139 in Idiopathic Pulmonary Fibrosis in the peer-reviewed publication European Respiratory Journal. The study highlights the effect of inhaled GB0139 in IPF patients on the plasma levels of highly relevant disease biomarkers, in particular YKL-40 and CCL-18, which have been shown to have prognostic significance in IPF. These and several other biomarkers were reduced in a dose dependent fashion from baseline in a consistent and statistically significant manner, with the strongest effects in the 10 mg dose group compared to placebo. GB0139, an inhaled small molecule inhibitor of galectin-3, a protein known to play a central role in fibrosis in several organs, has received Orphan Drug Designation from both the U.S. Food and Drug Administration and the European Medicines Agency for the treatment of IPF. The EMA cited clinically relevant biomarker data, in particular the significant reduction of YKL-40 in IPF patients, as a justification for the ODD designation. GB0139 was shown to be safe and well tolerated in healthy subjects and IPF patients in the phase 2a trial, and dose dependently suppressed expression of galectin-3, a protein known to play a central role in fibrosis in several organs, on alveolar macrophages. Galecto is now investigating GB0139 in the Phase 2b/3 GALACTIC-1 clinical trial in IPF. The trial is a pivotal size, randomized, double-blind, multicenter, parallel, placebo-controlled study across more than 100 centers in the U.S., the EU, and Canada, designed to evaluate the efficacy and safety of GB0139 in 450 subjects with IPF over 52 weeks.

ShowHide Related Items >><<
GLTO Galecto
$16.18 /

+0.18 (+1.13%)

11/23/20 SVB Leerink
SVB Leerink bullish on Galecto, initiates with an Outperform
11/23/20 SVB Leerink
Galecto initiated with an Outperform at SVB Leerink
11/23/20 Credit Suisse
Galecto initiated with an Outperform at Credit Suisse
11/23/20 BofA
Galecto initiated with a Buy at BofA
  • 29
    Oct
GLTO Galecto
$16.18 /

+0.18 (+1.13%)

Over a week ago
Initiation
SVB Leerink bullish on Galecto, initiates with an Outperform » 08:59
11/23/20
11/23
08:59
11/23/20
08:59
GLTO

Galecto

$16.14 /

+0.21 (+1.32%)

As previously reported,…

As previously reported, SVB Leerink analyst Thomas Smith initiated coverage of Galecto with an Outperform rating and $27 price target. The analyst believes investor expectations for the company's GB2064 and GB1211 are modest, given the history of failure for similar programs by others in the past. However, he sees the potential for Galecto's differentiated small molecule approach, which may have optimized selectivity and tissue access to improve on target activity.

ShowHide Related Items >><<
GLTO Galecto
$16.14 /

+0.21 (+1.32%)

11/23/20 SVB Leerink
Galecto initiated with an Outperform at SVB Leerink
11/23/20 Credit Suisse
Galecto initiated with an Outperform at Credit Suisse
11/23/20 BofA
Galecto initiated with a Buy at BofA
11/23/20 BofA
Galecto initiated with a Buy at BofA
  • 29
    Oct
GLTO Galecto
$16.14 /

+0.21 (+1.32%)

Initiation
Galecto initiated with an Outperform at SVB Leerink » 06:32
11/23/20
11/23
06:32
11/23/20
06:32
GLTO

Galecto

$16.14 /

+0.21 (+1.32%)

SVB Leerink analyst…

SVB Leerink analyst Thomas Smith initiated coverage of Galecto with an Outperform rating and $27 price target.

ShowHide Related Items >><<
GLTO Galecto
$16.14 /

+0.21 (+1.32%)

11/23/20 Credit Suisse
Galecto initiated with an Outperform at Credit Suisse
11/23/20 BofA
Galecto initiated with a Buy at BofA
11/23/20 BofA
Galecto initiated with a Buy at BofA
  • 29
    Oct
GLTO Galecto
$16.14 /

+0.21 (+1.32%)

Initiation
Galecto initiated with an Outperform at Credit Suisse » 06:29
11/23/20
11/23
06:29
11/23/20
06:29
GLTO

Galecto

$16.14 /

+0.21 (+1.32%)

Credit Suisse analyst…

Credit Suisse analyst Martin Auster initiated coverage of Galecto with an Outperform rating and $29 price target. The company is developing GB0139, an inhaled treatment testing a novel target for idiopathic pulmonary fibrosis, Auster tells investors in a research note. The analyst sees "substantial growth potential" for this market.

ShowHide Related Items >><<
GLTO Galecto
$16.14 /

+0.21 (+1.32%)

11/23/20 BofA
Galecto initiated with a Buy at BofA
11/23/20 BofA
Galecto initiated with a Buy at BofA
  • 29
    Oct
GLTO Galecto
$16.14 /

+0.21 (+1.32%)

Initiation
Galecto initiated with a Buy at BofA » 06:13
11/23/20
11/23
06:13
11/23/20
06:13
GLTO

Galecto

$16.14 /

+0.21 (+1.32%)

BofA analyst Geoff…

BofA analyst Geoff Meacham initiated coverage of Galecto with a Buy rating and $21 price target. The company is advancing multiple anti-fibrotic agents targeting galectin-3 and LOXL2 through mid-stage clinical studies, Meacham tells investors in a research note. The analyst sees "key points of differentiation from competitors" and believes Galecto can compete on improved safety and demonstrated impact on fibrosis.

ShowHide Related Items >><<
GLTO Galecto
$16.14 /

+0.21 (+1.32%)

11/23/20 BofA
Galecto initiated with a Buy at BofA
  • 29
    Oct
GLTO Galecto
$16.14 /

+0.21 (+1.32%)

Initiation
Galecto initiated with a Buy at BofA » 06:04
11/23/20
11/23
06:04
11/23/20
06:04
GLTO

Galecto

$16.14 /

+0.21 (+1.32%)

BofA initiated coverage…

BofA initiated coverage of Galecto with a Buy rating and $21 price target.

ShowHide Related Items >><<
  • 29
    Oct
GLTO Galecto
$16.14 /

+0.21 (+1.32%)

Over a month ago
On The Fly
Opening Day: MediaAlpha jumps 64%, Root falls flat in debut » 07:09
11/01/20
11/01
07:09
11/01/20
07:09
LU

Lufax

$12.85 /

+ (+0.00%)

, LMND

Lemonade

$50.02 /

+3.07 (+6.54%)

, DCT

Duck Creek Technologies

$42.95 /

-0.63 (-1.45%)

, AVIR

Atea Pharmaceuticals

$30.50 /

+ (+0.00%)

, SQZ

SQZ Biotechnologies

$13.24 /

+ (+0.00%)

, LESL

Leslie's

$21.92 /

+0.385 (+1.79%)

, ALGM

Allegro MicroSystems

$18.05 /

+0.43 (+2.44%)

, GLTO

Galecto

$15.00 /

+0.1 (+0.67%)

, BDSX

Biodesix

$13.49 /

+0.64 (+4.98%)

, ROOT

Root

$23.99 /

-1.825 (-7.07%)

, MAX

MediaAlpha

$33.88 /

+0.13 (+0.39%)

, GATO

Gatos Silver

$6.64 /

+0.075 (+1.14%)

, CONX

Conx

$0.00 /

+ (+0.00%)

, NBA

New Beginnings Acquisition

$0.00 /

+ (+0.00%)

, DSAC

Duddell Street Acquisition

$0.00 /

+ (+0.00%)

, AJAX

Ajax I

$0.00 /

+ (+0.00%)

, LUXA

Lux Health Tech Acquisition

$0.00 /

+ (+0.00%)

, AIRB

Use ABNB

$0.00 /

+ (+0.00%)

, CMPX

Compass Therapeutics

$0.00 /

+ (+0.00%)

, HOMS

Caliber Home Loans

$0.00 /

+ (+0.00%)

, WTM

White Mountains

$910.00 /

-2.38 (-0.26%)

MediaAlpha soared more…

ShowHide Related Items >><<
WTM White Mountains
$910.00 /

-2.38 (-0.26%)

LMND Lemonade
$50.02 /

+3.07 (+6.54%)

AIRB Use ABNB
$0.00 /

+ (+0.00%)

LU Lufax
$12.85 /

+ (+0.00%)

LMND Lemonade
$50.02 /

+3.07 (+6.54%)

10/15/20
Fly Intel: Pre-market Movers
10/15/20 Credit Suisse
Lemonade initiated with an Underperform at Credit Suisse
08/14/20 Morgan Stanley
Lemonade price target lowered to $70 from $91 at Morgan Stanley
07/27/20
Fly Intel: Top five analyst initiations
DCT Duck Creek Technologies
$42.95 /

-0.63 (-1.45%)

10/21/20 RBC Capital
Duck Creek Technologies price target raised to $51 from $45 at RBC Capital
10/21/20 Barclays
Duck Creek Technologies price target raised to $48 from $43 at Barclays
09/08/20 DA Davidson
Duck Creek Technologies initiated with a Buy at DA Davidson
09/08/20 Needham
Duck Creek Technologies initiated with a Buy at Needham
AVIR Atea Pharmaceuticals
$30.50 /

+ (+0.00%)

SQZ SQZ Biotechnologies
$13.24 /

+ (+0.00%)

LESL Leslie's
$21.92 /

+0.385 (+1.79%)

ALGM Allegro MicroSystems
$18.05 /

+0.43 (+2.44%)

GLTO Galecto
$15.00 /

+0.1 (+0.67%)

BDSX Biodesix
$13.49 /

+0.64 (+4.98%)

ROOT Root
$23.99 /

-1.825 (-7.07%)

MAX MediaAlpha
$33.88 /

+0.13 (+0.39%)

GATO Gatos Silver
$6.64 /

+0.075 (+1.14%)

CONX Conx
$0.00 /

+ (+0.00%)

NBA New Beginnings Acquisition
$0.00 /

+ (+0.00%)

DSAC Duddell Street Acquisition
$0.00 /

+ (+0.00%)

AJAX Ajax I
$0.00 /

+ (+0.00%)

LUXA Lux Health Tech Acquisition
$0.00 /

+ (+0.00%)

AIRB Use ABNB
$0.00 /

+ (+0.00%)

CMPX Compass Therapeutics
$0.00 /

+ (+0.00%)

HOMS Caliber Home Loans
$0.00 /

+ (+0.00%)

WTM White Mountains
$910.00 /

-2.38 (-0.26%)

LMND Lemonade
$50.02 /

+3.07 (+6.54%)

DCT Duck Creek Technologies
$42.95 /

-0.63 (-1.45%)

  • 28
    Oct
  • 30
    Oct
  • 30
    Oct
  • 29
    Oct
  • 29
    Oct
  • 29
    Oct
  • 30
    Oct
  • 29
    Oct
  • 28
    Oct
  • 28
    Oct
  • 28
    Oct
  • 14
    Aug
  • 02
    Jul
AIRB Use ABNB
$0.00 /

+ (+0.00%)

LMND Lemonade
$50.02 /

+3.07 (+6.54%)

LESL Leslie's
$21.92 /

+0.385 (+1.79%)

DCT Duck Creek Technologies
$42.95 /

-0.63 (-1.45%)

AIRB Use ABNB
$0.00 /

+ (+0.00%)

LMND Lemonade
$50.02 /

+3.07 (+6.54%)

DCT Duck Creek Technologies
$42.95 /

-0.63 (-1.45%)

Syndicate
Galecto opens at $15, IPO priced at $15 per share  10:34
10/29/20
10/29
10:34
10/29/20
10:34
GLTO

Galecto

$0.00 /

+ (+0.00%)

 
ShowHide Related Items >><<
  • 29
    Oct
Syndicate
Galecto indicated to open at $19.50, IPO priced at $15.00 » 10:25
10/29/20
10/29
10:25
10/29/20
10:25
GLTO

Galecto

$0.00 /

+ (+0.00%)

Galecto (GLTO) priced…

Galecto (GLTO) priced 5.667M shares at $15.00. The deal range was $14.00-$16.00. BofA, SVB Leerink and Credit Suisse acted as joint book running managers for the offering.

ShowHide Related Items >><<
  • 29
    Oct
Syndicate
Galecto 5.667M share IPO priced at $15.00 » 06:17
10/29/20
10/29
06:17
10/29/20
06:17
GLTO

Galecto

$0.00 /

+ (+0.00%)

The deal range was…

The deal range was $14.00-$16.00. BofA, SVB Leerink and Credit Suisse acted as joint book running managers for the offering.

ShowHide Related Items >><<
  • 29
    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.